Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
May 8, 2018
AAM
Recap of Access! 2018 — Successes From the Past Year (Part 1)
Blog
April 25, 2018
AAM
Together! Engaging Women in Health Policy
Blog
April 1, 2018
AAM
Why Membership Matters
Blog
March 28, 2018
AAM
Skyrocketing Drug Prices: What’s Driving Up Costs?
Blog
February 2, 2018
AAM
Help Pass the CREATES Act
Blog
January 31, 2018
AAM
Dear Mr. President
Blog
January 30, 2018
AAM
AAM Member Fresenius Kabi Testifies Before Congress on Drug Compounding
Blog
January 25, 2018
AAM
Anti-Competitive Evergreening Delays Patient Access to More Affordable Generics and Biosimilars
Blog
December 14, 2017
AAM
The Right People in the Room to Prevent Opioid Abuse on Campus
Blog
November 20, 2017
AAM
Recap: AAM’s FallTech Conference 2017
Blog
November 9, 2017
AAM
The Medicaid Generics Penalty: Barrier to Generic Competition (Part 3)
Blog
November 2, 2017
AAM
Five Reasons to Attend the 2017 FallTech Conference
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
